Literature DB >> 25427839

Pediatric germ cell tumors presenting beyond childhood?

J W Oosterhuis1, J A Stoop, M A Rijlaarsdam, K Biermann, V T H B M Smit, R Hersmus, L H J Looijenga.   

Abstract

Four cases are reported meeting the criteria of a pediatric (i.e., Type I) testicular germ cell tumor (TGCT), apart from the age of presentation, which is beyond childhood. The tumors encompass the full spectrum of histologies of pediatric TGCT: teratoma, yolk sac tumor, and various combinations of the two, and lack intratubular germ cell neoplasia/carcinoma in situ in the adjacent parenchyma. The neoplasms are (near)diploid, and lack gain of 12p, typical for seminomas and non-seminomas of the testis of adolescents and adults (i.e., Type II). It is proposed that these neoplasms are therefore late appearing pediatric (Type I) TGCT. The present report broadens the concept of earlier reported benign teratomas of the post-pubertal testis to the full spectrum of pediatric TGCT. The possible wide age range of pediatric TGCT, demonstrated in this study, lends credence to the concept that TGCT should according to their pathogenesis be classified into the previously proposed types. This classification is clinically relevant, because Type I mature teratomas are benign tumors, which are candidates for testis conserving surgery, as opposed to Type II mature teratomas, which have to be treated as Type II (malignant) non-seminomas.
© 2014 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  CIS testis; FISH; Johnsen score; aneuploidy; carcinoma in situ testis; isochromosome 12p; teratoma; testis conserving surgery; yolk sac tumor

Mesh:

Substances:

Year:  2014        PMID: 25427839     DOI: 10.1111/andr.305

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  6 in total

1.  More Cases of Benign Testicular Teratomas are Detected in Adults than in Children. A Clinicopathological Study of 543 Testicular Germ Cell Tumor Cases.

Authors:  Semjén David; Farkas András; Kalman Endre; Kaszas Balint; Kovács Árpad; Pusztai Csaba; Szuhai Karoly; Tornóczky Tamás
Journal:  Pathol Oncol Res       Date:  2016-10-28       Impact factor: 3.201

2.  Variants in BAK1, SPRY4, and GAB2 are associated with pediatric germ cell tumors: A report from the children's oncology group.

Authors:  Erin L Marcotte; Nathan Pankratz; James F Amatruda; A Lindsay Frazier; Mark Krailo; Stella Davies; Jacqueline R Starr; Ching C Lau; Michelle Roesler; Erica Langer; Caroline Hallstrom; Anthony J Hooten; Jenny N Poynter
Journal:  Genes Chromosomes Cancer       Date:  2017-04-04       Impact factor: 5.006

Review 3.  Testicular cancer.

Authors:  Liang Cheng; Peter Albers; Daniel M Berney; Darren R Feldman; Gedske Daugaard; Timothy Gilligan; Leendert H J Looijenga
Journal:  Nat Rev Dis Primers       Date:  2018-10-05       Impact factor: 52.329

4.  Testicular epidermoid cysts: a reevaluation.

Authors:  Petra Anheuser; J Kranz; E Stolle; D Höflmayer; F Büscheck; S Mühlstädt; G Lock; K P Dieckmann
Journal:  BMC Urol       Date:  2019-06-11       Impact factor: 2.264

5.  Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology.

Authors:  Gabriele Calaminus; Dominik T Schneider; Dietrich von Schweinitz; Heribert Jürgens; Nacera Infed; Stefan Schönberger; Thomas A Olson; Peter Albers; Christian Vokuhl; Raimund Stein; Leendert Looijenga; Jalid Sehouli; Martin Metzelder; Alexander Claviez; Michael Dworzak; Angelika Eggert; Birgit Fröhlich; Nicolas U Gerber; Christian P Kratz; Jörg Faber; Thomas Klingebiel; Dieter Harms; Ulrich Göbel
Journal:  Cancers (Basel)       Date:  2020-03-06       Impact factor: 6.639

Review 6.  Predicting Gonadal Germ Cell Cancer in People with Disorders of Sex Development; Insights from Developmental Biology.

Authors:  Leendert H J Looijenga; Chia-Sui Kao; Muhammad T Idrees
Journal:  Int J Mol Sci       Date:  2019-10-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.